Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78520 | 0.87 | DGAT1 (0.46) | DGAT1ALDH1A1CA12CA14CA2 | |
| Hydrazine SCHEMBL10794464 | 0.81 | DGAT1 (0.42) | DGAT1ALDH1A1CA12CA14CA2 | |
| SCHEMBL7440249 | 0.81 | DGAT1 (0.44) | DGAT1ALDH1A1TET2CA12CA14 | |
| SCHEMBL29233535 | 0.81 | DGAT1 (0.40) | DGAT1ALDH1A1TET2CA12CA14 | |
| SCHEMBL4147427 | 0.79 | ALDH1A1 (0.44) | DGAT1ALDH1A1TET2CA12CA14 | |
| SCHEMBL29399642 | 0.78 | — | — | |
| SCHEMBL1820007 | 0.78 | ALDH1A1 (0.68) | DGAT1ALDH1A1TET2CA12CA14 | |
| SCHEMBL1798280 | 0.78 | ALDH1A1 (0.68) | DGAT1ALDH1A1TET2CA12CA14 | |
| SCHEMBL6950834 | 0.77 | ALDH1A1 (0.56) | ALDH1A1TET2CA2GAAEGLN1 | |
| SCHEMBL8295 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102234231-B | 1-substituted-2-substituted-4- aryl substituted-butyl-2-alkene 1, 4-diketone compound, its preparation method and application | SHANGHAI INST MATERIA MEDICA | 2015-01-07 | — | — | CN | claimed |
| CN-103420894-A | 2- butane-1,4-diketone compounds, preparation method and applications | SHANGHAI INST MATERIA MEDICA | 2013-12-04 | — | — | CN | claimed |
| CN-102234231-A | 1-substituted-2-substituted-4- aryl substituted-butyl-2-alkene 1, 4-diketone compound, its preparation method and application | SHANGHAI INST MATERIA MEDICA | 2011-11-09 | — | — | CN | claimed |
| CN-1569803-B | Process for preparing aryl beta-diketo acid | SHANGHAI INST MATERIA MEDICA | 2011-04-13 | — | — | CN | claimed |
| CN-1569803-A | Process for preparing aryl beta-diketo acid | SHANGHAI INST MATERIA MEDICA (CN) | 2005-01-26 | — | — | CN | claimed |
| EP-4496787-B1 | THIOL-OXAMIDE COMPOUNDS AND COMPOSITIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250100964-A1 | Thiol-Oxamide Compounds and Compositions | 3M INNOVATIVE PROPERTIES COMPANY | 2025-03-27 | — | — | US | disclosed |
| EP-4496787-A1 | THIOL-OXAMIDE COMPOUNDS AND COMPOSITIONS | 3M Innovative Properties Company (US) | 2025-01-29 | — | — | EP | disclosed |
| CN-115427522-B | Aqueous resin particle dispersion | 爱克发有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4237469-B1 | CURED ADHESIVE COMPOSITIONS AND METHOD OF MAKING | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-116390970-B | Cured adhesive composition and method of making the same | 舒万诺知识产权公司 | 2024-04-26 | — | — | CN | disclosed |
| US-11964073-B2 | Cured adhesive compositions and method of making | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2024-04-23 | — | — | US | disclosed |
| US-20130217693-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-08-22 | — | — | US | disclosed |
| US-20130217693-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-08-22 | — | — | US | disclosed |
| CN-102234231-A | 1-substituted-2-substituted-4- aryl substituted-butyl-2-alkene 1, 4-diketone compound, its preparation method and application | SHANGHAI INST MATERIA MEDICA | 2011-11-09 | — | — | CN | disclosed |
| CN-1569803-B | Process for preparing aryl beta-diketo acid | SHANGHAI INST MATERIA MEDICA | 2011-04-13 | — | — | CN | disclosed |
| US-20090088444-A1 | Substituted phenanthrene diketo acids and uses therefor | BUOLAMWINI JOHN K | 2009-04-02 | — | — | US | disclosed |
| US-20050090668-A1 | Preparation of 5-hydroxy-6-oxo-1,6-dihydropyrimidine compounds | DREHER SPENCER D (US) | 2005-04-28 | — | — | US | disclosed |
| CN-1569803-A | Process for preparing aryl beta-diketo acid | SHANGHAI INST MATERIA MEDICA (CN) | 2005-01-26 | — | — | CN | disclosed |
| EP-0286145-A2 | 3-Heterocyclylthiomethyl cephalosporins | SANKEI PHARMACEUTICAL COMPANY LIMITED (JP) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088444-A1 | Substituted phenanthrene diketo acids and uses therefor | WEE1, WEE2, HADHB | DGAT1 1607/4885ALDH1A1 1119/4885TET2 3552/4885 |
| US-20050090668-A1 | Preparation of 5-hydroxy-6-oxo-1,6-dihydropyrimidine compounds | DPYD, DHODH, DHPS | DGAT1 821/4885ALDH1A1 856/4885TET2 1051/4885 |
| US-20130217693-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | NNT, CCR5, XDH | DGAT1 3670/4885ALDH1A1 3325/4885TET2 3472/4885 |
| US-20250100964-A1 | Thiol-Oxamide Compounds and Compositions | TMT1A, TST, SULT1E1 | DGAT1 3790/4885ALDH1A1 110/4885TET2 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.